Global Anemia Drugs Market (Iron Deficiency, Sickle Cell, CKD, Aplastic Anemia): Analysis By Region, By Country (2016-2021) (By Type - Iron Deficiency Anemia, Chronic Kidney Disease related Anemia, Sickle Cell Anemia, Aplastic Anemia; By Region-North America, Europe, APAC, Latin America, MEA; By Country - USA, Canada, UK, Germany, India, Brazil, South Africa)
Executive Summary
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of global anemia drugs market on the basis of Type (Iron Deficiency Anemia, Chronic Kidney Disease related Anemia, Sickle Cell Anemia, Aplastic Anemia), By Region (North America, Europe, APAC, Latin America, MEA); By Country (USA, Canada, UK, Germany, India, Brazil, South Africa).
Rising development of pipeline drugs combined with the growing awareness of disease in developing countries has resulted in the growth of Anemia Drugs market. Anemia Drugs has been majorly caused due to the lack of iron intake and less iron absorption mainly among pregnant women, women of reproductive age and young children.
Among the various types of anemia, market is expected to be driven by CKD anemia, due to the growing research and development towards new biosimilars such as Hypoxia-inducible factors. However, launch of late pipeline drugs such as Rivipansel and Vepoloxamer for sickle cell anemia treatment are anticipated to drive the market in forecast period.
While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population.
Global Anemia Drugs Market is forecasted to grow at a CAGR of 9.05% during 2016 – 2021F, on account of rising incidences of anemia globally.
North America region remains the major market followed by Europe in the actual period, while APAC and ROW region will witness strong growth in the forecast period.
According to Azoth Analytics research report, Global Anemia Drugs Market: Trends, Opportunities and Forecasts (2016-2021), Global Anemia Drugs market is projected to exhibit a CAGR of over ~9.05% during 2016 - 2021. On the basis of market segment, Global Anemia Drugs Market has been segmented by Type (Iron Deficiency Anemia, Chronic Kidney Disease related Anemia, Sickle Cell Anemia, Aplastic Anemia); By Region-North America, Europe, APAC, Latin America, MEA; By Country-USA, Canada, UK, Germany, India, Brazil, South Africa)
Scope of the Report
The report provides Segmentation and Pipeline Analysis by Anemia Type
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of global anemia drugs market on the basis of Type (Iron Deficiency Anemia, Chronic Kidney Disease related Anemia, Sickle Cell Anemia, Aplastic Anemia), By Region (North America, Europe, APAC, Latin America, MEA); By Country (USA, Canada, UK, Germany, India, Brazil, South Africa).
Rising development of pipeline drugs combined with the growing awareness of disease in developing countries has resulted in the growth of Anemia Drugs market. Anemia Drugs has been majorly caused due to the lack of iron intake and less iron absorption mainly among pregnant women, women of reproductive age and young children.
Among the various types of anemia, market is expected to be driven by CKD anemia, due to the growing research and development towards new biosimilars such as Hypoxia-inducible factors. However, launch of late pipeline drugs such as Rivipansel and Vepoloxamer for sickle cell anemia treatment are anticipated to drive the market in forecast period.
While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population.
Global Anemia Drugs Market is forecasted to grow at a CAGR of 9.05% during 2016 – 2021F, on account of rising incidences of anemia globally.
North America region remains the major market followed by Europe in the actual period, while APAC and ROW region will witness strong growth in the forecast period.
According to Azoth Analytics research report, Global Anemia Drugs Market: Trends, Opportunities and Forecasts (2016-2021), Global Anemia Drugs market is projected to exhibit a CAGR of over ~9.05% during 2016 - 2021. On the basis of market segment, Global Anemia Drugs Market has been segmented by Type (Iron Deficiency Anemia, Chronic Kidney Disease related Anemia, Sickle Cell Anemia, Aplastic Anemia); By Region-North America, Europe, APAC, Latin America, MEA; By Country-USA, Canada, UK, Germany, India, Brazil, South Africa)
Scope of the Report
The report provides Segmentation and Pipeline Analysis by Anemia Type
- Iron Deficiency Anemia
- Chronic Kidney Disease related Anemia
- Sickle Cell Anemia
- Aplastic Anemia
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
- USA
- Canada
- UK
- Germany
- India
- Brazil
- South Africa
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
1. RESEARCH METHODOLOGY
2. EXECUTIVE SUMMARY
3. STRATEGIC RECOMMENDATIONS
3.1. North America and Europe to Generate High Revenue
3.2. Opportunity in Rare Anemia
3.3. Growing Inclination Towards Hypoxia inducible factor (HIF) Stabilizers
4. GLOBAL ANEMIA DRUGS MARKET: AN OVERVIEW
4.1. Product Overview
4.2. Global Anemia Drugs Market
4.1.1. By Value (Historic 2011-15)
4.1.2. By Value (Forecast 2016E-2021F)
4.3. Global Iron Deficiency Anemia Drugs Market
4.2.1. By Value (Historic 2011-15)
4.2.2. By Value (Forecast 2016E-2021F)
4.4. Global CKD Anemia Drugs Market
4.4.1. By Value (Historic 2011-15)
4.4.2. By Value (Forecast 2016E-2021F)
4.5. Global Sickle Cell Anemia Drugs Market
4.5.1. By Value (Historic 2011-15)
4.5.2. By Value ( Forecast 2016E-2021F)
4.6. Global Aplastic Anemia Drugs Market
4.6.1. By Value (Historic 2011-15)
4.6.2. By Value ( Forecast 2016E-2021F)
4.7. Anemia Drugs Pipeline Analysis
4.7.1. Sickle Cell Anemia
4.7.2. CKD Anemia
4.7.3. Aplastic Anemia
4.7.4. Iron Deficiency Anemia
4.7.5. Myelodysplastic syndrome Anemia
5. NORTH AMERICA ANEMIA DRUGS MARKET: AN ANALYSIS
5.1. North America Anemia Drugs Market
5.1.1.By Value (Historic 2011-15)
5.1.2.By Value (Forecast 2016E-2021F)
5.2. North America Anemia Drugs Market: Country Overview – US, Canada
6. EUROPE ANEMIA DRUGS MARKET: AN ANALYSIS
6.1. Europe Anemia Drugs Market
6.1.1. By Value (Historic 2011-15)
6.1.2. By Value (Forecast 2016E-2021F)
6.2. Europe Anemia Drugs Market: Country Overview – UK, Germany
7. APAC ANEMIA DRUGS MARKET: AN ANALYSIS
7.1. APAC Anemia Drugs Market
7.1.1.By Value (Historic 2011-15)
7.1.2.By Value (Forecast 2016E-2021F)
7.2. North America Anemia Drugs Market: Country Overview – India
8. LATIN AMERICA ANEMIA DRUGS MARKET: AN ANALYSIS
8.1. Latin America Anemia Drugs Market
8.1.1.By Value (Historic 2011-15)
8.1.2.By Value (Forecast 2016E-2021F)
8.2. Latin America Anemia Drugs Market: Country Overview – Brazil
9. MEA ANEMIA DRUGS MARKET: AN ANALYSIS
9.1. MEA Anemia Drugs Market
9.1.1.By Value (Historic 2011-15)
9.1.2.By Value (Forecast 2016E-2021F)
9.2. MEA Anemia Drugs Market: Country Overview – South Africa
10. MARKET DYNAMICS
10.1. Trends
10.2. Drivers
10.3. Challenges
11. M&A AND LICENSING ROUTE TO THE ANEMIA DRUGS TREATMENT MARKET
12. SWOT ANALYSIS
13. PORTER FIVE FORCE MODEL
14. COMPANY PROFILING AND DRUG MARKET POTENTIAL
Sickle Cell Anaemia
14.1. Global Blood Therapeutics (GBT)
14.1.1. Company Overview
14.1.2. GBT-440 (Drug of Global Blood Therapeutics)
14.1.2.1 Market Potential
14.2. Bluebird bio
14.2.1. Company Overview
14.2.2. LentiGlobin BB305 (Drug of Bluebird bio)
14.2.2.1 Stage of development
14.2.2.2 Overview
14.2.2.3 Clinical Data
14.2.2.4 Market Potential
14.3. GlycoMimetics
14.3.1. Company Overview
14.3.2. Rivipansel (Drug of GlycoMimetics)
14.3.2.1 Stage of development
14.3.2.2 Overview
14.3.2.3 Clinical Data
14.3.2.4 Market Opportunity
14.4.Mast Therapeutics
14.4.1. Company Overview
14.4.2. Vepoloxamer (Drug of Mast Therapeutics)
14.4.2.1 Stage of development
14.4.2.2 Overview
14.4.2.3 Clinical Data
14.4.2.4 Market Potential
CKD Anemia
14.5. GlaxoSmithKline
14.5.1. Company Overview
14.5.2. Daprodustat (Drug of GlaxoSmithKline)
14.5.2.1 Stage of development
14.5.2.2 Overview
14.5.2.3 Clinical Data
14.6. Fibrogen
14.6.1. Company Overview
14.6.2. Roxadustat (Drug of Fibrogen)
14.6.2.1 Stage of development
14.6.2.2 Overview
14.6.2.3 Clinical Data
14.7. Akebia therapeutics
14.7.1. Company Overview
14.7.2. Vadadustat (Product of Akebia therapeutics)
14.7.2.1 Stage of development
14.7.2.2 Overview
14.7.2.3 Clinical Data
14.8. Bayer AG
14.8.1. Company Overview
14.8.2. Molidustat (Drug of Bayer)
14.8.2.1 Stage of development
14.8.2.2 Overview
14.8.2.3 Clinical Data
14.9. Eli Lilly
14.9.1. Company Overview
14.9.2. BMP-6 Mab (Drug of Eli Lilly)
14.9.2.1 Stage of development
14.9.2.2 Overview
14.9.2.3 Clinical Data
14.9.3. Sotatercept (Drug of Eli Lilly)
14.9.3.1 Stage of development
14.9.3.2 Overview
14.9.3.3 Clinical Data
Aplastic Anemia
14.10. Regen biopharma
14.10.1. Hemaxellerate (Product of Regen biopharma)
14.10.1.1 Overview
14.10.1.2 Stage of development
14.10.2 BL-8040 (Drug of Bioline RX)
14.10.2.1 Overview
14.10.2.2 Stage of development
14.10.2.3 Clinical Data
Myelodysplastic syndrome
14.11. Acceleron Pharma
14.12. Celgene Corporation
14.12.1. Luspatercept (Drug of Acceleron Pharma and Celgene Corporation)
14.12.1.1 Overview
14.12.1.2 Stage of development
14.12.1.3 Clinical Data
14.13. Onconova Therapeutics
14.13.1 Luspatercept (Drug of Acceleron Pharma and Celgene Corporation)
14.13.1.1 Overview
14.13.1.2 Stage of development
14.13.1.3 Clinical Data
Iron Deficiency Anemia
14.14. Pieris Pharmaceuticals
14.14.1. PRS-080 (Drug of Pieris Pharmaceuticals)
14.14.1.1 Overview
14.14.1.2 Stage of development
14.14.1.3 Clinical Data
2. EXECUTIVE SUMMARY
3. STRATEGIC RECOMMENDATIONS
3.1. North America and Europe to Generate High Revenue
3.2. Opportunity in Rare Anemia
3.3. Growing Inclination Towards Hypoxia inducible factor (HIF) Stabilizers
4. GLOBAL ANEMIA DRUGS MARKET: AN OVERVIEW
4.1. Product Overview
4.2. Global Anemia Drugs Market
4.1.1. By Value (Historic 2011-15)
4.1.2. By Value (Forecast 2016E-2021F)
4.3. Global Iron Deficiency Anemia Drugs Market
4.2.1. By Value (Historic 2011-15)
4.2.2. By Value (Forecast 2016E-2021F)
4.4. Global CKD Anemia Drugs Market
4.4.1. By Value (Historic 2011-15)
4.4.2. By Value (Forecast 2016E-2021F)
4.5. Global Sickle Cell Anemia Drugs Market
4.5.1. By Value (Historic 2011-15)
4.5.2. By Value ( Forecast 2016E-2021F)
4.6. Global Aplastic Anemia Drugs Market
4.6.1. By Value (Historic 2011-15)
4.6.2. By Value ( Forecast 2016E-2021F)
4.7. Anemia Drugs Pipeline Analysis
4.7.1. Sickle Cell Anemia
4.7.2. CKD Anemia
4.7.3. Aplastic Anemia
4.7.4. Iron Deficiency Anemia
4.7.5. Myelodysplastic syndrome Anemia
5. NORTH AMERICA ANEMIA DRUGS MARKET: AN ANALYSIS
5.1. North America Anemia Drugs Market
5.1.1.By Value (Historic 2011-15)
5.1.2.By Value (Forecast 2016E-2021F)
5.2. North America Anemia Drugs Market: Country Overview – US, Canada
6. EUROPE ANEMIA DRUGS MARKET: AN ANALYSIS
6.1. Europe Anemia Drugs Market
6.1.1. By Value (Historic 2011-15)
6.1.2. By Value (Forecast 2016E-2021F)
6.2. Europe Anemia Drugs Market: Country Overview – UK, Germany
7. APAC ANEMIA DRUGS MARKET: AN ANALYSIS
7.1. APAC Anemia Drugs Market
7.1.1.By Value (Historic 2011-15)
7.1.2.By Value (Forecast 2016E-2021F)
7.2. North America Anemia Drugs Market: Country Overview – India
8. LATIN AMERICA ANEMIA DRUGS MARKET: AN ANALYSIS
8.1. Latin America Anemia Drugs Market
8.1.1.By Value (Historic 2011-15)
8.1.2.By Value (Forecast 2016E-2021F)
8.2. Latin America Anemia Drugs Market: Country Overview – Brazil
9. MEA ANEMIA DRUGS MARKET: AN ANALYSIS
9.1. MEA Anemia Drugs Market
9.1.1.By Value (Historic 2011-15)
9.1.2.By Value (Forecast 2016E-2021F)
9.2. MEA Anemia Drugs Market: Country Overview – South Africa
10. MARKET DYNAMICS
10.1. Trends
10.2. Drivers
10.3. Challenges
11. M&A AND LICENSING ROUTE TO THE ANEMIA DRUGS TREATMENT MARKET
12. SWOT ANALYSIS
13. PORTER FIVE FORCE MODEL
14. COMPANY PROFILING AND DRUG MARKET POTENTIAL
Sickle Cell Anaemia
14.1. Global Blood Therapeutics (GBT)
14.1.1. Company Overview
14.1.2. GBT-440 (Drug of Global Blood Therapeutics)
14.1.2.1 Market Potential
14.2. Bluebird bio
14.2.1. Company Overview
14.2.2. LentiGlobin BB305 (Drug of Bluebird bio)
14.2.2.1 Stage of development
14.2.2.2 Overview
14.2.2.3 Clinical Data
14.2.2.4 Market Potential
14.3. GlycoMimetics
14.3.1. Company Overview
14.3.2. Rivipansel (Drug of GlycoMimetics)
14.3.2.1 Stage of development
14.3.2.2 Overview
14.3.2.3 Clinical Data
14.3.2.4 Market Opportunity
14.4.Mast Therapeutics
14.4.1. Company Overview
14.4.2. Vepoloxamer (Drug of Mast Therapeutics)
14.4.2.1 Stage of development
14.4.2.2 Overview
14.4.2.3 Clinical Data
14.4.2.4 Market Potential
CKD Anemia
14.5. GlaxoSmithKline
14.5.1. Company Overview
14.5.2. Daprodustat (Drug of GlaxoSmithKline)
14.5.2.1 Stage of development
14.5.2.2 Overview
14.5.2.3 Clinical Data
14.6. Fibrogen
14.6.1. Company Overview
14.6.2. Roxadustat (Drug of Fibrogen)
14.6.2.1 Stage of development
14.6.2.2 Overview
14.6.2.3 Clinical Data
14.7. Akebia therapeutics
14.7.1. Company Overview
14.7.2. Vadadustat (Product of Akebia therapeutics)
14.7.2.1 Stage of development
14.7.2.2 Overview
14.7.2.3 Clinical Data
14.8. Bayer AG
14.8.1. Company Overview
14.8.2. Molidustat (Drug of Bayer)
14.8.2.1 Stage of development
14.8.2.2 Overview
14.8.2.3 Clinical Data
14.9. Eli Lilly
14.9.1. Company Overview
14.9.2. BMP-6 Mab (Drug of Eli Lilly)
14.9.2.1 Stage of development
14.9.2.2 Overview
14.9.2.3 Clinical Data
14.9.3. Sotatercept (Drug of Eli Lilly)
14.9.3.1 Stage of development
14.9.3.2 Overview
14.9.3.3 Clinical Data
Aplastic Anemia
14.10. Regen biopharma
14.10.1. Hemaxellerate (Product of Regen biopharma)
14.10.1.1 Overview
14.10.1.2 Stage of development
14.10.2 BL-8040 (Drug of Bioline RX)
14.10.2.1 Overview
14.10.2.2 Stage of development
14.10.2.3 Clinical Data
Myelodysplastic syndrome
14.11. Acceleron Pharma
14.12. Celgene Corporation
14.12.1. Luspatercept (Drug of Acceleron Pharma and Celgene Corporation)
14.12.1.1 Overview
14.12.1.2 Stage of development
14.12.1.3 Clinical Data
14.13. Onconova Therapeutics
14.13.1 Luspatercept (Drug of Acceleron Pharma and Celgene Corporation)
14.13.1.1 Overview
14.13.1.2 Stage of development
14.13.1.3 Clinical Data
Iron Deficiency Anemia
14.14. Pieris Pharmaceuticals
14.14.1. PRS-080 (Drug of Pieris Pharmaceuticals)
14.14.1.1 Overview
14.14.1.2 Stage of development
14.14.1.3 Clinical Data
